Katia Cannita
Overview
Explore the profile of Katia Cannita including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
1288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krasniqi E, Filomeno L, Arcuri T, Di Lisa F, Astone A, Cutigni C, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682290
Background/objectives: HER2-positive breast cancer (HER2BC) is an aggressive subtype, with neoadjuvant treatment (NAT) aiming to achieve a pathological complete response (pCR) to improve long-term outcomes. Trastuzumab emtansine (T-DM1) has been...
2.
Irelli A, Patruno L, Chiatamone Ranieri S, Di Giacomo D, Malatesta S, Alesse E, et al.
Biomedicines
. 2024 Apr;
12(4).
PMID: 38672070
Hereditary breast and ovarian cancer (HBOC) syndrome is responsible for approximately 10% of breast cancers (BCs). The HBOC gene panel includes both high-risk genes, i.e., a four times higher risk...
3.
Bianchi A, Zelli V, DAngelo A, Di Matteo A, Scoccia G, Cannita K, et al.
NAR Genom Bioinform
. 2024 Apr;
6(2):lqae033.
PMID: 38633426
In the rapidly evolving field of genomics, understanding the genetic basis of complex diseases like breast cancer, particularly its familial/hereditary forms, is crucial. Current methods often examine genomic variants-such as...
4.
Irelli A, Ceriello L, Patruno L, Tessitore A, Alesse E, Cannita K, et al.
Biomedicines
. 2024 Jan;
12(1).
PMID: 38255284
Pertuzumab and trastuzumab have been shown to improve the outcomes of patients with metastatic breast cancer, with a rate of left ventricular dysfunction of approximately 6%. We report the case...
5.
Di Lisa F, Krasniqi E, Pizzuti L, Barba M, Cannita K, De Giorgi U, et al.
Front Oncol
. 2023 Jun;
13:1152123.
PMID: 37260975
Background: In triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine,...
6.
Cortellini A, DAlessio A, Cleary S, Buti S, Bersanelli M, Bordi P, et al.
Clin Cancer Res
. 2023 May;
29(14):2714-2724.
PMID: 37125965
Purpose: No evidence exists as to whether type 2 diabetes mellitus (T2DM) impairs clinical outcome from immune checkpoint inhibitors (ICI) in patients with solid tumors. Experimental Design: In a large...
7.
Irelli A, Chiatamone Ranieri S, Di Giacomo D, Malatesta S, Patruno L, Tessitore A, et al.
Cancers (Basel)
. 2023 Mar;
15(6).
PMID: 36980613
Molecular tumor boards (MTBs) are multidisciplinary groups that combine molecular and clinical data from cancer patients in order to formulate treatment recommendations for precision medicine. To date, there is insufficient...
8.
Irelli A, Parisi A, DOrazio C, Sidoni T, Rotondaro S, Patruno L, et al.
Cancers (Basel)
. 2022 Jun;
14(12).
PMID: 35740668
HER2 is considered one of the most traditional prognostic and predictive biomarkers in breast cancer. Literature data confirmed that the addition of pertuzumab to a standard neoadjuvant chemotherapy backbone (either...
9.
DIncecco A, Cannita K, Martella F, DE Vico A, Zaccagna G, Landi L, et al.
J Thorac Dis
. 2022 May;
14(4):805-808.
PMID: 35572878
No abstract available.
10.
Zelli V, Parisi A, Patruno L, Cannita K, Ficorella C, Luzi C, et al.
Front Oncol
. 2022 Apr;
12:863639.
PMID: 35463316
The assessment of and mutational status is one of the main steps in the diagnostic and therapeutic algorithm of metastatic colorectal cancer (mCRC). Multiple mutations in the BRAF and RAS...